Latest Content

New data reveals a rising trend in generalized anxiety disorder (GAD) prevalence among U.S. adults, emphasizing the need for improved diagnosis and treatment.

An abstract presented at AMCP Nexus 2025 showed that Medicaid drug spend in 10 states in FY 2023 was approximately equal to or less than the national drug spending rate of 14%.

Critics say it doesn’t address the misalignment and a shift from the major PBMs collecting fees instead of rebates.

A study at AMCP Nexus 2025 reveals how drug rebates and net prices influence insurance coverage for specialty drugs, impacting patient access.

An abstract presented at AMCP Nexus 2025 showed the overuse of opioids following successful cancer treatment is detrimental to patient health and expensive.

Self-injected Brekiya (dihydroergotamine mesylate) is now available by prescription for patients suffering from cluster headaches and migraines with aura.

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 Fall Clinical Dermatology conference.

In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.

Here’s what you missed this week on Managed Healthcare Executive.

Mona Shahriari, M.D., dermatologist at Central Connecticut Dermatology and an associate clinical professor at Yale School of Medicine discusses the highlights of her session called ‘Seeing Clearly: A Visual Guide to Diagnosing Prurigo Nodularis in Skin of Color.’

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Expensive, newer therapies and a lack of pediatric data are roadblocks to advancing treatment for pediatric atopic dermatitis, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, gives an overview of his session at the 2025 Fall Clinical Dermatology Conference.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, discusses why his clinic has shifted towards earlier atopic dermatitis treatment for patients.

Shawn Kwatra, M.D., reveals new OX40 ligand therapies for atopic dermatitis, promising new hope for patients at the Fall Clinical Dermatology meeting.

Shawn Kwatra addresses the complexities of atopic dermatitis and prurigo nodularis at the Fall Clinical Dermatology Conference, emphasizing tailored treatment strategies.

Employer health premiums rose significantly this year, impacting healthcare costs and insurance access. A KFF survey reveals trends in coverage and employee contributions.

Study participants who used the mPATH-Lung program were 60% more likely to undergo lung cancer screening, than particpants who did not use the program.

A greater understanding of the association between multiple sclerosis (MS) and the oral microbiome may lead to less invasive dialogistic markers and novel treatment options for patients, according to this recent study by researchers at the University of Iowa Health Care.

Rebyota improves quality of life for patients with recurrent C. difficile (C. diff) infections, according to two analyses of real-world data presented at IDWeek 2025.

New findings reveal aflibercept 8 mg enhances vision and extends injection intervals for nAMD and DME patients, reducing treatment burden significantly.

Experts reveal strategies to improve breast cancer screening and outcomes for underserved communities, addressing disparities during Breast Cancer Awareness Month.

Socioeconomic factors are a key risk factor for Type 2 diabetes, but a new analysis says the same is not true when it comes to Type 1 diabetes.

New research reveals AREDS vitamins do not slow geographic atrophy progression in AMD, urging patients to explore FDA-approved treatments instead.

Gazyva is the first and only anti-CD20 monoclonal antibody approved to treat kidney inflammation associated with lupus.

Here’s what you missed this week on Managed Healthcare Executive.

At the American Academy of Ophthalmology meeting, Andrew G. Lee, M.D., explained that El Nino and La Nina weather patterns — worsened by climate change — can worsen eye conditions such as dry eye, cataracts, infections and UV-related damage while also influencing disease outbreaks and access to care.

A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated patients extending dosing intervals two weeks.